Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 04

288P - Impact of hormonal contraception on estradiol and progesterone serum levels: A 6-year study on progression-free survival, disease-free survival, and overall survival at Dr. Moewardi Hospital

Date

03 Dec 2022

Session

Poster viewing 04

Topics

Tumour Site

Breast Cancer

Presenters

Widyanti Soewoto

Citation

Annals of Oncology (2022) 33 (suppl_9): S1540-S1546. 10.1016/annonc/annonc1131

Authors

W. Soewoto

Author affiliations

  • Surgical Oncology Departement, Medical Faculty of Sebelas Maret University, 57126 - Surakarta/ID

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 288P

Background

The family planning program curated by the Indonesian government to limit population growth has been successful. Hormonal contraception contains progesterone and estrogen, risk factors for breast cancer. Breast cancer is a prominent health issue in Indonesia as it has a high incidence rate and accounts for the second-highest mortality in women. the purpose of this research, looking at how the effect of hormonal contraceptives on estradiol and progesterone levels in breast cancer patients.

Methods

a six-year prospective cohort study at Dr. Moewardi Hospital. There are two groups of subjects with and without hormonal contraceptives. Data on breast cancer stage, tumor characteristics, estradiol levels, and progesterone levels were collected. The data are presented in mean, standard deviation, and distribution frequency (%). Statistical tests using Chi-square, Fisher exact, Mann-Whitney, and an independent t-test.

Results

303 samples were aged 31 to 78 years. 51% grade III, 28.7% Luminal B, and 45.9% LABC. 54.1% high estradiol levels, and 80.5% normal progesterone levels. The use of contraceptives, the type, duration of use, and duration of discontinuation of contraceptives do not affect estradiol and progesterone levels (p>0.05). Estradiol levels affect PFS, DFS, and OS (p<0.05) while progesterone levels have no effect (p>0.05). The type and duration of contraceptive use do not affect PFS, DFS, and OS (p>0.05). While the duration of discontinuation of contraceptives affects the OS (p<0.05) but not PFS and DFS (p>0.05).

Conclusions

PFS, DFS, and OS in breast cancer are affected by significantly high levels of estradiol, and in contrast, progesterone levels tend to be normal and not significantly affected. Lower levels of estradiol are associated with a better OS. A shorter duration for stopping the use of contraceptives is associated with a worse OS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.